✓ Translated by DotMD AI Clinical Council Source: American journal of cardiovascular drugs : drugs, devices, and other interventions • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #37395974 ↗

Phase III Randomized Trial: A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia (N = 145)

Original Paper Title: “A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 145
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • A/L/R/E as an SPC could be an effective treatment for patients with hypertension and dyslipidemia without significant safety issues.
  • Study Design & Sample: Phase III Randomized Trial published in American journal of cardiovascular drugs : drugs, devices, and other interventions (N = 145 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in American journal of cardiovascular drugs : drugs, devices, and other interventions (2023), this phase iii randomized trial evaluating 145 human participants investigated: Few data are available regarding the efficacy and safety of a single-pill combination (SPC) consisting of four medications in patients with concomitant hypertension and dyslipidemia. Key clinical takeaway: A/L/R/E as an SPC could be an effective treatment for patients with hypertension and dyslipidemia without significant safety issues.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023-07-15; N = 145; Rigor 88/100): A/L/R/E as an SPC could be an effective treatment for patients with hypertension and dyslipidemia without significant safety issues.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: bio-combination-28-schuessler-salts → Rx: amlodipine-besylate → Rx: amlodipine → Rx: losartan-potassium → Condition: cholesterol → Condition: atherosclerotic-dyslipidemia-apob → Condition: lipid-metabolism-disorders →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37395974: Phase III Randomized Trial: A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia (N = 145)

3 of 3 Free Questions Remaining